WO2020055360A2 - The parenteral composition comprising carfilzomib - Google Patents

The parenteral composition comprising carfilzomib Download PDF

Info

Publication number
WO2020055360A2
WO2020055360A2 PCT/TR2019/050580 TR2019050580W WO2020055360A2 WO 2020055360 A2 WO2020055360 A2 WO 2020055360A2 TR 2019050580 W TR2019050580 W TR 2019050580W WO 2020055360 A2 WO2020055360 A2 WO 2020055360A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
parenteral composition
mixtures
acid
parenteral
Prior art date
Application number
PCT/TR2019/050580
Other languages
French (fr)
Other versions
WO2020055360A3 (en
Inventor
Ali Turkyilmaz
Irem Yenice
Ali Ihsan SECKIN
Yuksel TOPALOGLU
Original Assignee
Arven Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arven Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Arven Ilac Sanayi Ve Ticaret Anonim Sirketi
Publication of WO2020055360A2 publication Critical patent/WO2020055360A2/en
Publication of WO2020055360A3 publication Critical patent/WO2020055360A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Definitions

  • the present invention relates to a parenteral composition comprising carfilzomib or a pharmaceutically acceptable salt thereof. Furthermore, the composition is obtained using an effective process.
  • Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
  • Multiple myeloma is a cancer that forms in a type of white blood cell called a plasma cell. Plasma cells help you fight infections by making antibodies that recognize and attack germs. Multiple myeloma causes cancer cells to accumulate in the bone marrow, where they crowd out healthy blood cells.
  • the clinical features are bone pain, renal impairment, immunodeficiency, anemia and presence of abnormal immunoglobulins.
  • Carfilzomib is a modified tetrapeptidyl epoxide, isolated as the crystalline free base.
  • the chemical name for carfilzomib is (2S)-N-((S)-1 -((S)-4-methyl-1 -((R)-2-methyloxiran- 2-yl)-1 - oxopentan -2-ylcarbamoyl)- 2- phenylethyl)- 2- ((S)-2-(2-morpholinoacetamido)-4- phenyl butanamido)-4-methylpentanamide.
  • Carfilzomib has the following structure:
  • Carfilzomib is a selective proteasome inhibitor indicated for the treatment of cancer, particularly multiple myeloma.
  • Carfilzomib is commercially marketed under the name Kyprolis ® in single dose vials containing either 30 mg or 60 mg of the active ingredient.
  • Each vial in addition to lyophilized carfilzomib, also contains sulfobutylether beta-cyclodextrin, citric acid and sodium hydroxide for pH adjustment (target pH 3.5).
  • U.S. Patent No.7, 417,042 discloses a process for the preparation of carfilzomib.
  • U.S. Patent No. 8,367,617 discloses crystalline carfilzomib, a citrate salt of carfilzomib, and amorphous carfilzomib.
  • WO20161 16882 discloses a pharmaceutical composition comprising carfilzomib, one or more sugars, an acidifying agent.
  • the main object of the present invention is to provide a stable composition comprising carfilzomib or pharmaceutically acceptable salt thereof.
  • Another object of the present invention is to provide desired solubility, permeability, pharmacokinetics and/or pharmacodynamics properties.
  • the present invention provides a process for producing a lyophilized pharmaceutical composition comprising carfilzomib.
  • parenteral means modes of administration other than enteral and topical administration, usually by injection, and comprising intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrastemal injection, and infusion.
  • a parenteral composition comprising carfilzomib or a pharmaceutically acceptable salt thereof, at least one acid stabilizers and at least one surfactants.
  • the acid stabilizers are selected from the group comprising succinic, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, lactic, phosphoric, sulfuric, tartaric, maleic, malic, mandelic, methanesulfonic, p-toluenesulfonic, chloroacetic acids or mixtures thereof.
  • the acid stabilizer is succinic or acetic or mixtures thereof.
  • the pH of the acid stabilizers is from 2 to 4, preferably pH of the acid stabilizers is 3.5.
  • Surfactants offer many advantages. One of these is the use of surfactants becomes inevitable to reduce the interfacial tension between the medium and the drug and to increase solubility of drugs. Since carfilzomib has low molarity, the choice of surfactant is of great importance.
  • Suitable the surfactants are selected from the group comprising macrogol 15 hydroxystearate, macrogolglycerol ricinoleate 35, polyoxyethylene sorbitan esters (polysorbate), sodium lauryl sulphate, propylene glycol, glyceryl oleate, tocopherol, ascorbyl palmitate, citric acid, polyethoxylated fatty acid esters, polyoxyethylene hydrogenated castor oil, sorbitan esters, docusate sodium, nonoxynol or mixtures thereof.
  • the surfactant is macrogol 15 hydroxystearate or macrogolglycerol ricinoleate 35 or mixtures thereof. Due to stability issues, carfilzomib containing compositions must be lyophilized before storage and reconstituted before use.
  • the composition is a stable lyophilized powder for injection.
  • lyophilized refers to freeze drying processes in which a material is frozen at cold temperatures and reduced pressure to sublimate water and other solvents present.
  • Lyoprotectant is added to a formulation in order to protect the active ingredient during both freezing and drying process.
  • Lyoprotectants are selected from the group comprising amino acids and sugars.
  • the composition further comprises at least one the lyoprotectant which is selected from amino acids.
  • Suitable the amino acids are selected from the group comprising L-cysteine, glycine, proline, 4-hydroxyproline, L-serine, sodium glutamate, alanine, arginine, lysine hydrochloride, di- or tri-amino acids or mixtures thereof.
  • the amino acid is L-cysteine.
  • the composition is free of sugars.
  • Said sugars is mannitol or sucrose or glucose or lactose or trehalose or glycine or dextrose or maltose or sorbitol or dextran or raffinose.
  • the composition further comprises the solvents and co-solvents which is selected from the group comprising tertiary butyl alcohol, water for injection, dimethyl sulfoxide (DMSO), N,N- dimethylacetamide (DMA), acetonitrile, lower alkanols, ethyl acetate, propylene glycol (PG), polyethylene glycol, glycerine or mixtures thereof.
  • Buffering agents encompasses those agents which maintain the composition pH in an acceptable range prior to lyophilization. Many buffering agents covering a wide pH range are available for selection in the formulations.
  • the composition further comprises at least one the buffering agent which is selected from the group comprising sodium hydroxide (NaOH), sodium phosphate, acetate, citrate, glycine, histidine, potassium phosphate, diethanolamine, tris or mixtures thereof.
  • NaOH sodium hydroxide
  • sodium phosphate sodium phosphate
  • acetate citrate
  • glycine glycine
  • histidine histidine
  • potassium phosphate diethanolamine
  • tris tris or mixtures thereof.
  • the composition further comprises chelating agent for increase the solubility like ethylenediaminetetraacetic acid (EDTA), optionally.
  • EDTA ethylenediaminetetraacetic acid
  • the composition is ready-to-dilute.
  • the composition is for use in treating cancer.
  • the cancer is selected from the group comprising multiple myeloma, head and neck cancers, esophagus cancer, gastric cancer, colorectal cancer, colon cancer, rectum cancer, liver cancer, gallbladder cancer, cholangiocarcinoma, biliary tract cancer, pancreatic cancer, lung cancer, breast cancer, ovarian cancer, cervical cancer, endometrial cancer, vaginal cancer, vulvar cancer, renal cancer, urothelial cancer, prostate cancer, testicular tumor, osteosarcoma, soft-tissue sarcoma, leukemia, myelodysplastic syndrome, malignant lymphoma, adult T-cell leukemia, skin cancer, brain tumor, pleural mesothelioma, and unknown primary cancer.
  • the cancer is multiple myeloma.
  • step (a) b) adding tert-butyl alcohol in step (a) mixture
  • Vials are loaded in a lyophilizer and freeze dried.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a parenteral composition comprising carfilzomib or a pharmaceutically acceptable salt thereof. Furthermore, the composition is obtained using an effective process.

Description

THE PARENTERAL COMPOSITION COMPRISING CARFILZOMIB Field of the invention
The present invention relates to a parenteral composition comprising carfilzomib or a pharmaceutically acceptable salt thereof. Furthermore, the composition is obtained using an effective process.
Background of the invention
Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Multiple myeloma is a cancer that forms in a type of white blood cell called a plasma cell. Plasma cells help you fight infections by making antibodies that recognize and attack germs. Multiple myeloma causes cancer cells to accumulate in the bone marrow, where they crowd out healthy blood cells. The clinical features are bone pain, renal impairment, immunodeficiency, anemia and presence of abnormal immunoglobulins.
Carfilzomib is a modified tetrapeptidyl epoxide, isolated as the crystalline free base. The chemical name for carfilzomib is (2S)-N-((S)-1 -((S)-4-methyl-1 -((R)-2-methyloxiran- 2-yl)-1 - oxopentan -2-ylcarbamoyl)- 2- phenylethyl)- 2- ((S)-2-(2-morpholinoacetamido)-4- phenyl butanamido)-4-methylpentanamide. Carfilzomib has the following structure:
Figure imgf000002_0001
Formula I
Carfilzomib is a selective proteasome inhibitor indicated for the treatment of cancer, particularly multiple myeloma.
Carfilzomib is commercially marketed under the name Kyprolis® in single dose vials containing either 30 mg or 60 mg of the active ingredient. Each vial, in addition to lyophilized carfilzomib, also contains sulfobutylether beta-cyclodextrin, citric acid and sodium hydroxide for pH adjustment (target pH 3.5).
U.S. Patent No.7, 417,042, discloses a process for the preparation of carfilzomib. U.S. Patent No. 8,367,617, discloses crystalline carfilzomib, a citrate salt of carfilzomib, and amorphous carfilzomib.
WO20161 16882 (A2) discloses a pharmaceutical composition comprising carfilzomib, one or more sugars, an acidifying agent.
As carfilzomib has low aqueous solubility, the development of a stable parenteral composition comprising carfilzomib is very challenging.
Therefore, there is still need for a parenteral composition comprising carfilzomib that has desired stability and solubility.
Surprisingly, in the present invention, a stable parenteral composition of carfilzomib has been developed using the non-aqueous environment which overcomes the above drawbacks.
Detailed description of the Invention
The main object of the present invention is to provide a stable composition comprising carfilzomib or pharmaceutically acceptable salt thereof.
Another object of the present invention is to provide desired solubility, permeability, pharmacokinetics and/or pharmacodynamics properties.
The present invention provides a process for producing a lyophilized pharmaceutical composition comprising carfilzomib.
The term“parenteral” as used herein means modes of administration other than enteral and topical administration, usually by injection, and comprising intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrastemal injection, and infusion. According to one embodiment of the present invention, a parenteral composition comprising carfilzomib or a pharmaceutically acceptable salt thereof, at least one acid stabilizers and at least one surfactants.
Surprisingly, it has been found that the antimicrobial activity and stability of the carfilzomib is dependent on the pH value of the composition.
So, chemical stability can be substantially improved by lowering the pH value and by increasing the buffer capacity in order to provide an adjusted and robustly maintained pH value. It has been surprisingly found that using acid stabilizer provide very stable composition comprising carfilzomib.
According to one embodiment of the present invention, the acid stabilizers are selected from the group comprising succinic, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, lactic, phosphoric, sulfuric, tartaric, maleic, malic, mandelic, methanesulfonic, p-toluenesulfonic, chloroacetic acids or mixtures thereof. Preferably, the acid stabilizer is succinic or acetic or mixtures thereof.
According to one embodiment of the present invention, the pH of the acid stabilizers is from 2 to 4, preferably pH of the acid stabilizers is 3.5.
Surfactants offer many advantages. One of these is the use of surfactants becomes inevitable to reduce the interfacial tension between the medium and the drug and to increase solubility of drugs. Since carfilzomib has low molarity, the choice of surfactant is of great importance.
Suitable the surfactants are selected from the group comprising macrogol 15 hydroxystearate, macrogolglycerol ricinoleate 35, polyoxyethylene sorbitan esters (polysorbate), sodium lauryl sulphate, propylene glycol, glyceryl oleate, tocopherol, ascorbyl palmitate, citric acid, polyethoxylated fatty acid esters, polyoxyethylene hydrogenated castor oil, sorbitan esters, docusate sodium, nonoxynol or mixtures thereof.
According to one embodiment of the present invention, the surfactant is macrogol 15 hydroxystearate or macrogolglycerol ricinoleate 35 or mixtures thereof. Due to stability issues, carfilzomib containing compositions must be lyophilized before storage and reconstituted before use.
According to one embodiment of the present invention, the composition is a stable lyophilized powder for injection.
The term "lyophilized" refers to freeze drying processes in which a material is frozen at cold temperatures and reduced pressure to sublimate water and other solvents present.
Lyoprotectant is added to a formulation in order to protect the active ingredient during both freezing and drying process. Lyoprotectants are selected from the group comprising amino acids and sugars.
According to one embodiment of the present invention, the composition further comprises at least one the lyoprotectant which is selected from amino acids.
Suitable the amino acids are selected from the group comprising L-cysteine, glycine, proline, 4-hydroxyproline, L-serine, sodium glutamate, alanine, arginine, lysine hydrochloride, di- or tri-amino acids or mixtures thereof.
According to one embodiment of the present invention, the amino acid is L-cysteine.
In the formulation, using sugars as lyoprotectant with acid causes non-volatile sugar acids. It may create stability problems for the composition comprising carfilzomib.
According to one embodiment of the present invention, the composition is free of sugars. Said sugars is mannitol or sucrose or glucose or lactose or trehalose or glycine or dextrose or maltose or sorbitol or dextran or raffinose.
According to one embodiment of the present invention, the composition further comprises the solvents and co-solvents which is selected from the group comprising tertiary butyl alcohol, water for injection, dimethyl sulfoxide (DMSO), N,N- dimethylacetamide (DMA), acetonitrile, lower alkanols, ethyl acetate, propylene glycol (PG), polyethylene glycol, glycerine or mixtures thereof. Buffering agents encompasses those agents which maintain the composition pH in an acceptable range prior to lyophilization. Many buffering agents covering a wide pH range are available for selection in the formulations.
According to one embodiment of the present invention, the composition further comprises at least one the buffering agent which is selected from the group comprising sodium hydroxide (NaOH), sodium phosphate, acetate, citrate, glycine, histidine, potassium phosphate, diethanolamine, tris or mixtures thereof.
According to one embodiment of the present invention, the composition further comprises chelating agent for increase the solubility like ethylenediaminetetraacetic acid (EDTA), optionally.
According to one embodiment of the present invention, the composition is ready-to-dilute. The composition is for use in treating cancer.
According to an embodiment of the present invention, the cancer is selected from the group comprising multiple myeloma, head and neck cancers, esophagus cancer, gastric cancer, colorectal cancer, colon cancer, rectum cancer, liver cancer, gallbladder cancer, cholangiocarcinoma, biliary tract cancer, pancreatic cancer, lung cancer, breast cancer, ovarian cancer, cervical cancer, endometrial cancer, vaginal cancer, vulvar cancer, renal cancer, urothelial cancer, prostate cancer, testicular tumor, osteosarcoma, soft-tissue sarcoma, leukemia, myelodysplastic syndrome, malignant lymphoma, adult T-cell leukemia, skin cancer, brain tumor, pleural mesothelioma, and unknown primary cancer.
According to one embodiment of the present invention, the cancer is multiple myeloma.
Example 1 :
Figure imgf000007_0001
Process a) dissolving surfactant(s) in water for injection,
b) adding tert-butyl alcohol in step (a) mixture,
c) adding L-cysteine and adjusting to pH 1.7 with acid stabilizer(s), d) cooling the mixture until 5°C,
e) adding carfilzomib gradually until a clear solution is obtained, f) adjusting to pH 3.5 with NaOH,
g) this solution is filtered through a 0.45m membrane filter h) filling in vials as per the fill volume
i) Vials are loaded in a lyophilizer and freeze dried.

Claims

1 . A parenteral composition comprising carfilzomib or a pharmaceutically acceptable salt thereof, at least one acid stabilizers and at least one surfactants.
2. The parenteral composition according to claim 1 , wherein the acid stabilizers are selected from the group comprising succinic, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, lactic, phosphoric, sulfuric, tartaric, maleic, malic, mandelic, methanesulfonic, p-toluenesulfonic, chloroacetic acids or mixtures thereof.
3. The parenteral composition according to claim 2, wherein the acid stabilizer is succinic or acetic or mixtures thereof.
4. The parenteral composition according to claim 3, wherein the pH of the acid stabilizers is from 2 to 4, preferably pH of the acid stabilizers is 3.5.
5. The parenteral composition according to claim 1 , wherein the surfactants are selected from the group comprising macrogol 15 hydroxystearate, macrogolglycerol ricinoleate 35, polyoxyethylene sorbitan esters (polysorbate), sodium lauryl sulphate, propylene glycol, glyceryl oleate, tocopherol, ascorbyl palmitate, citric acid, polyethoxylated fatty acid esters, polyoxyethylene hydrogenated castor oil, sorbitan esters, docusate sodium, nonoxynol or mixtures thereof.
6. The parenteral composition according to claim 5, wherein the surfactant is macrogol 15 hydroxystearate or macrogolglycerol ricinoleate 35 or mixtures thereof.
7. The parenteral composition according to claim 1 , wherein the composition is lyophilized powder for injection.
8. The parenteral composition according to claim 7, wherein further comprising at least one the lyoprotectant which is selected from amino acids.
9. The parenteral composition according to claim 8, wherein the amino acids are selected from the group comprising L-cysteine, glycine, proline, 4-hydroxyproline, L- serine, sodium glutamate, alanine, arginine, lysine hydrochloride, di- or tri-amino acids or mixtures thereof.
10. The parenteral composition according to claim 9, wherein the amino acid is L- cysteine.
1 1. The parenteral composition according to any preceding claim, wherein the composition is free of sugars.
12. The parenteral composition according to claim 1 1 , wherein said sugars is mannitol or sucrose or glucose or lactose or trehalose or glycine or dextrose or maltose or sorbitol or dextran or raffinose.
13. The parenteral composition according to any preceding claim, wherein further comprising the solvents and co-solvents which is selected from the group comprising tertiary butyl alcohol, water for injection, dimethyl sulfoxide (DMSO), N,N- dimethylacetamide (DMA), acetonitrile, lower alkanols, ethyl acetate, propylene glycol (PG), polyethylene glycol, glycerine or mixtures thereof.
14. The parenteral composition according to any preceding claim, wherein further comprising at least one the buffering agent which is selected from the group comprising sodium hydroxide (NaOH), sodium phosphate, acetate, citrate, glycine, histidine, potassium phosphate, diethanolamine, tris or mixtures thereof.
15. The parenteral composition according to any preceding claim, wherein further comprising chelating agent optionally, preferably chelating agent is EDTA.
16. The parenteral composition according to any preceding claim, wherein the composition is ready-to-dilute.
17. The parenteral composition according to any preceding claim for use in treating cancer.
18. The parenteral composition according to claim 17, wherein the cancer is multiple myeloma.
PCT/TR2019/050580 2018-08-10 2019-07-16 The parenteral composition comprising carfilzomib WO2020055360A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201811693 2018-08-10
TR2018/11693 2018-08-10

Publications (2)

Publication Number Publication Date
WO2020055360A2 true WO2020055360A2 (en) 2020-03-19
WO2020055360A3 WO2020055360A3 (en) 2020-06-04

Family

ID=69777254

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2019/050580 WO2020055360A2 (en) 2018-08-10 2019-07-16 The parenteral composition comprising carfilzomib

Country Status (1)

Country Link
WO (1) WO2020055360A2 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008340429C1 (en) * 2007-12-21 2016-09-08 F. Hoffmann-La Roche Ag Antibody formulation
WO2016116882A2 (en) * 2015-01-23 2016-07-28 Leiutis Pharmaceuticals Pvt Ltd Novel compositions of carfilzomib
US10098890B2 (en) * 2016-10-29 2018-10-16 Cipla Limited Stable carfilzomib formulations
US11224631B2 (en) * 2017-01-24 2022-01-18 Orbicular Pharmaceutical Technologies Pvt. Ltd. Ready-to-use Carfilzomib compositions

Also Published As

Publication number Publication date
WO2020055360A3 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
JP6042412B2 (en) Lyophilized preparation of cytotoxic dipeptide
JP5914486B2 (en) Caspofungin composition
JP7229999B2 (en) Daptomycin preparation
US10253031B2 (en) Stable pemetrexed arginine salt and compositions comprising it
JP6182262B2 (en) Stable water-soluble pharmaceutical composition containing anticancer agent
JP6461945B2 (en) Process for producing a lyophilized pharmaceutical composition having a content of mitomycin C
JP2014507426A (en) Medicinal composition containing Mikafungin, an echinocandin antifungal agent, and production method and use thereof
JP2007500191A (en) Freeze-dried formulation of CCI-779
JP6882538B2 (en) Composition for injection
JPWO2008020584A1 (en) Stable lyophilized formulation
JP4142149B2 (en) Vancomycin lyophilized formulation
KR20200052326A (en) Formulation of Copanlis
US20120283304A1 (en) Formulations of Temozolomide for Parenteral Administration
WO2020055360A2 (en) The parenteral composition comprising carfilzomib
WO2017085696A1 (en) Parenteral formulations of melphalan
CA3121428A1 (en) Novel pharmaceutical formulation
KR102194376B1 (en) Lyophilized preparation of cytotoxic dipeptides
US20230068866A1 (en) Daptomycin formulation
US20140275122A1 (en) Voriconazole Formulations
JP5389910B2 (en) Stable lyophilized formulations of anthracycline compounds
EA023081B1 (en) Injectable dosage form of flupirtine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19860518

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19860518

Country of ref document: EP

Kind code of ref document: A2